Prednisone
NDC Package 43063-703-18

11-digit billing NDC: 43063070318 · Billing unit: EA · 18 EA per package
Table of Contents
    1. Package Information
    2. Other Packages
    3. Frequently Asked Questions

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was discontinued by the firm.

Prednisone is tablets, USP are indicated in the following conditions:1. Marketed by Pd-rx Pharmaceuticals, Inc., this product is identified by NDC 43063-703 and is authorized under FDA application ANDA040362.

Identification & Billing

NDC Package Code
43063-703-18
Package Description
18 TABLET in 1 BOTTLE, PLASTIC
Product Code
43063-703
11-Digit Billing Format
43063070318
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
18 EA

Clinical Specifications

Proprietary Name
Prednisone
Dosage Form
-
Usage Information
Prednisone Tablets, USP are indicated in the following conditions:1. Endocrine DisordersPrimary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis 2. Rheumatic DisordersAs adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in:Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis. 3. Collagen DiseasesDuring an exacerbation or as maintenance therapy in selected cases of:Systemic lupus erythematosus Systemic derznatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic DiseasesPemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic StatesControl of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment:Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis             Serum sickness            Drug hypersensitivity reactions 6. Ophthalmic DiseasesSevere acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as:Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory DiseasesSymptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Aspiration pneumonitis 8. Hematologic DisordersIdiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic DiseasesFor palliative management of:Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous StatesTo induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus11. Gastrointestinal DiseasesTo tide the patient over a critical period of the disease in:Ulcerative colitis Regional enteritis 12. Nervous SystemAcute exacerbations of multiple sclerosis13. MiscellaneousTuberculous meningitis with subarachnoid block or, impending block when used concurrently  with appropriate antituberculous chemotherapy            Trichinosis with neurologic or myocardial involvement

Regulatory & Marketing

Labeler Name
Pd-rx Pharmaceuticals, Inc.
FDA Application #
ANDA040362
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
08-29-2001
End Marketing Date
05-01-2026
Listing Expiration
05-01-2026
Exclude Flag
D
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (43063-703). Click a package code to view its specific billing and regulatory data.

43063-703-05
5 TABLET in 1 BOTTLE, PLASTIC
43063-703-06
6 TABLET in 1 BOTTLE, PLASTIC
43063-703-09
9 TABLET in 1 BOTTLE, PLASTIC
43063-703-10
10 TABLET in 1 BOTTLE, PLASTIC
43063-703-12
12 TABLET in 1 BOTTLE, PLASTIC
43063-703-14
14 TABLET in 1 BOTTLE, PLASTIC
43063-703-15
15 TABLET in 1 BOTTLE, PLASTIC
43063-703-20
20 TABLET in 1 BOTTLE, PLASTIC
43063-703-21
21 TABLET in 1 BOTTLE, PLASTIC
43063-703-25
25 TABLET in 1 BOTTLE, PLASTIC
43063-703-30
30 TABLET in 1 BOTTLE, PLASTIC

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 43063-703-18 identifies a specific commercial package of 18 tablet in 1 bottle, plastic of Prednisone, labeled by Pd-rx Pharmaceuticals, Inc.. This product is billed for "EA" each discreet unit and contains an estimated amount of 18 billable units per package. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Pd-rx Pharmaceuticals, Inc. on August 29, 2001. The current certification is valid through May 01, 2026.

How is this Pd-rx Pharmaceuticals, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 43063070318. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 18 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
43063-703-18
11-Digit CMS (5-4-2)
43063-0703-18

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.